Form 4: Supernus CEO Sells Shares After Option Exercise

Supernus Pharmaceuticals CEO Jack Khattar sold shares after exercising stock options under a pre-arranged 10b5-1 plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions involving company common stock.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 14, 2024.
• On August 27, 2025, Mr. Khattar exercised options to acquire 17,195 shares of common stock at an exercise price of $12.98 per share.
• Concurrently, on August 27, 2025, he sold 10,650 shares of common stock at a weighted average price of $45.05 per share, with prices ranging from $45.00 to $45.10.
• On August 28, 2025, he exercised options to acquire an additional 38,779 shares of common stock at an exercise price of $12.98 per share.
• On the same day, August 28, 2025, he sold 24,150 shares of common stock at a weighted average price of $45.12 per share, with prices ranging from $45.00 to $45.26.
• Following these transactions, Mr. Khattar directly beneficially owns 1,092,633 shares of common stock and indirectly owns 1,005,600 shares through the KBT Trust.
• The employee stock options vested in four equal installments beginning March 1, 2017, and have an expiration date of March 1, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be a negative signal, the fact that it's under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. It primarily reflects an executive monetizing vested compensation.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planning and reducing concerns about opportunistic insider selling.
• The executive is realizing value from previously granted stock options, reflecting past appreciation in the company's stock price.

Negatives

• The sale of shares by a key executive, even if pre-planned, can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Risks

• Potential for negative market sentiment or misinterpretation of the insider selling, despite the existence of a 10b5-1 plan.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

These transactions represent routine executive compensation activity, where an executive exercises vested stock options and sells a portion of the acquired shares, often for diversification or liquidity purposes. Such activities are common across publicly traded companies, particularly within the pharmaceutical sector where executive compensation packages frequently include equity-based incentives.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance, providing an affirmative defense against insider trading allegations by pre-scheduling transactions.
• The realization of significant gains from stock options, with sale prices substantially higher than the exercise price, is typical for executives in companies with appreciating stock values, comparable to similar events at peer pharmaceutical companies like Jazz Pharmaceuticals or Acadia Pharmaceuticals where executives monetize equity incentives.

Corporate Governance

Related Party Transactions

• Mr. Khattar indirectly beneficially owns 1,005,600 shares through the KBT Trust, which is a related party.

Stakeholder Impact

• Shareholders may observe the insider selling and potentially react to the volume of shares sold, although the 10b5-1 plan provides context.
• Employees may view the executive's monetization of options as a positive sign of the company's past performance and value creation.

Key Dates

Recommendation

The filing details routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. While insider selling can sometimes be a negative signal, the planned nature of these transactions suggests they are for personal financial management rather than a reflection of a change in the company's fundamental outlook. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further company-specific or market-wide developments.

Keywords

SUPN, Supernus Pharmaceuticals, Jack Khattar, Insider Trading, Form 4, Stock Options, Executive Compensation, 10b5-1 Plan